Efficacy of sodium-glucose co-transporter 2 inhibitors combined with metformin in the treatment of elderly type 2 diabetes mellitus and their effect on renal function
Efficacy of sodium-glucose co-transporter 2 inhibitors combined with metformin in the treatment of elderly type 2 diabetes mellitus and their effect on renal function
Objective To investigate the clinical effect of sodium-glucose co-transporter 2(SGLT-2)inhib-itor combined with metformin in the treatment of type 2 diabetes mellitus in the elderly and its effect on re-nal function.Methods A total of 102 elderly patients with type 2 diabetes mellitus diagnosed and treated by Xinglong Community Health Service Center in Jianye District,Nanjing from October 2020 to October 2022 were grouped into random number tables,the control group(51 cases)were treated with metformin hydrochloride tablets,and the observation group(51 cases)was treated with dapagliflozin tablets combined with metformin hydrochloride tablets,and the blood glucose indexes,blood glucose indexes,renal function in-dexes and drug safety were compared between the two groups before treatment and 12 weeks after treatments.Results After treatment,compared with the control group,the levels of blood glucose(2 h PG),glycated hemoglobin(HbA1c)and fasting blood glucose(FPG)decreased significantly in the observation group(P<0.05),compared with the control group,the levels of urea nitrogen(BUN),cystatin C(CysC),serum creatinine(Scr),and urine micro-albumin(mALB)decreased significantly(P<0.05),and the incidence of adverse reactions in the observation group(13.73%)Compared with the control group(9.80%),the difference was not statistically significant(P>0.05).Conclusion SGLT-2 inhibitors combined with met-formin in the treatment of elderly type 2 diabetes mellitus can enhance hypoglycemic effect and promote renal function improvement,without significantly increasing adverse reactions.
关键词
2型糖尿病/血糖/药物治疗/肾功能
Key words
Type 2 diabetes/Blood sugar/Drug therapy/Kidney function
维普
万方数据